The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients

In this study, we investigated the effect of pre-treatment with demethylating agent decitabine on susceptibility to chemotherapeutic drugs in HL60/ADR, Kasumi-1 and primary AML cells. Cytotoxic effect was increased by decitabine through activation of p53 and inhibition of c-Myc, Survivin and Bcl-2....

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Xuejie, Wang, Zhixiang, Ding, Bingjie, Yin, Changxin, Zhong, Qingxiu, Carter, Bing Z., Yu, Guopan, Jiang, Ling, Ye, Jieyu, Dai, Min, Zhang, Yu, Liang, Shuang, Zhao, Qingxia, Liu, Qifa, Meng, Fanyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741789/
https://www.ncbi.nlm.nih.gov/pubmed/26384351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741789/
https://www.ncbi.nlm.nih.gov/pubmed/26384351

Ejemplares similares